BioSpace News Archive

OSE Immunotherapeutics SA announced the departure of Alexis Peyroles as Chief Executive Officer.

Daiichi Sankyo Company, Limited and AstraZeneca have received notification of acceptance by the U.S. Food and Drug Administration of the supplemental Biologics License Application of ENHERTU® for the treatment of adult patients in the U.S. with unresectable or metastatic HER2 positive breast cancer who have received a prior anti-HER2-based regimen.

XPhyto Therapeutics Corp. is pleased to announce the appointment of Mr. Drahoslav Zdarek as the Company’s Head of Sales, Europe.

The Philippines has approved Recombinant Two-Component COVID-19 Vaccine developed by Jiangsu Recbio Technology Co., Ltd. for Phase II/III clinical research.

Ryvu Therapeutics, a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced the appointment of Hendrik Nogai, M.D. to the role of Chief Medical Officer effective February 1st, 2022.

Neurimmune AG announced that it has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd.

First PCR test for parasites detects 20 intestinal parasites, emerging threats like treatment-resistant hookworm and zoonotic Giardia.

Vigil Health Solutions Inc. (“ Vigil ” or the “ Company ”) (TSXV: VGL) announced today that it has entered into an arrangement agreement (the “ Arrangement Agreement ”) with ABLOY Canada Inc. (the “ Purchaser ”), a subsidiary within the ASSA ABLOY Group (“ ASSA ABLOY ”),pursuant to which the Purchaser will acquire all of Vigil’s issued and outstanding common shares at a price of $0.67 per share in cash (the “ Transaction ”).

Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, February 1, 2022 , at 8:00 a.m. CST to review second quarter fiscal 2022 financial results.

Boundless Bio today announced that Peter Krein has been appointed as Vice President of Precision Medicine.